Drug Trial Radar · NCT01502774
Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
970
Actual
Start
Apr 2011
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Hospices Civils de LyonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Infarct size is a major determinant of prognosis after Acute Myocardial Infarction (AMI). The investigators recently reported that cyclosporine A, when administered immediately prior to percutaneous coronary intervention (PCI), can significantly reduce infarct size in STEMI (ST Elevation acute Myocardial Infarction) patients. The objective of the present study is to determine whether cyclosporine can improve STEMI patient clinical outcome. Nine-hundred and seventy two patients with ST elevation MI will be entered into a multicentre, randomized, placebo-controlled, double-blinded study. They will receive one single injection of cyclosporine A (CicloMulsion, verum) or an equivalent volume of placebo prior to reperfusion therapy by PCI. The incidence of the combined endpoint (mortality, hospitalization for heart failure, left ventricular (LV) remodeling) will be assessed at one year and three years after treatment.
Conditions
- ST Elevation Acute Myocardial Infarction
Interventions
Injection of CyclosporinDrug
one single intravenous bolus injection of 2.5 mg/Kg
PlaceboDrug
One single intravenous bolus injection of Placebo
EchocardiographyProcedure
1 year after AMI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined incidence of [total mortality; hospitalization for heart failure; LV remodeling (increase of LV end-diastolic volume > 15%)]Time frame: at 1 year post-AMI
Locations
45 sites in 3 countries. Site status is shown where the registry gives one.
Algemeen Ziekenhuis Sint-Jan Brugge
Bruges, Belgium
Chu Charleroi
Charleroi, Belgium
Hôpital universitaire d'Anvers (UZA)
Edegem, Belgium
CHU Mont-Godinne
Yvoir, Belgium
Clinique ESQUIROL - SAINT-HILAIRE
Agen, France
Centre Hospitalier du Pays D'Aix
Aix-en-Provence, France
Centre Hospitalier Universitaire d'Angers
Angers, France
Centre Hospitalier d'Annecy
Annecy, France
Hôpital Henri Duffaut
Avignon, France
Clinique Lafourcade
Bayonne, France
Centre Hospitalier Universitaire
Brest, France
Hopital Louis Pradel, Hospices Civils de Lyon
Bron, France
CHRU- Hôpital de la Côte de Nacre
Caen, France
Centre Hospitalier General
Chartres, France
CHU - Hôpital Gabriel Montpied
Clermont-Ferrand, France
CH de Compiègne
Compiègne, France
CH Henri MONDOR
Créteil, France
Hôpital du Bocage
Dijon, France
Hôpital A. MICHALLON - CHU
Grenoble, France
Centre Hospitalier General
Haguenau, France
CHRU - Hôpital Cardiologique Calmette
Lille, France
Clinique de la Sauvegarde
Lyon, France
Centre Hospitalier St Luc St Joseph
Lyon, France
Institut Jacques Cartier
Massy, France
CHU Arnaud de Villeneuve
Montpellier, France
Clinique du Millénaire
Montpellier, France
CHU de Mulhouse
Mulhouse, France
Clinique du Diaconat
Mulhouse, France
Hôpital Guillaume et René Laennec
Nantes, France
CHU de Nîmes
Nîmes, France
Polyclinique des Fleurs
Ollioules, France
APHP Hôpital Bichat
Paris, France
CH de Pau
Pau, France
Hôpital Haut Lévêque
Pessac, France
Hôpital Claude Galien
Quincy-sous-Sénart, France
Hôpital Pontchaillou
Rennes, France
Hôpital Charles NICOLLE
Rouen, France
Hôpitaux Universitaires, Nouvel Hôpital Civil
Strasbourg, France
Clinique de l'Ormeau - CCV des Pyrénées
Tarbes, France
CHU de Rangueil
Toulouse, France
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.